Paper Details

  1. Home
  2. Paper Details

Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses.

Author: NguyenH P, RiversJ K

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

5-FU-SA, a topical formulation of 5-fluorouracil and salicylic acid, is effective in treating grade I/II actinic keratosis, and is a patient-applied therapeutic option.
Paper Details　
Original Abstract of the Article :
Actinic keratosis (AK), a common cutaneous lesion with the potential to transform into squamous cell carcinoma, has traditionally been treated with ablative and/or surgical procedures. Recently, a topical formulation combining 0.5% 5-fluorouracil with 10% salicylic acid (5-FU-SA) was introduced in E...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/27223248

データ提供：米国国立医学図書館（NLM）

Actikerall™: A New Topical Solution for Treating Actinic Keratoses

This research introduces [Actikerall™], a novel topical solution for treating [actinic keratoses (AKs)], precancerous skin lesions that can progress to [squamous cell carcinoma]. The study examines the efficacy and safety of Actikerall™, comparing it to [diclofenac 3% gel] in a randomized clinical trial. The findings suggest that Actikerall™ may be a promising new treatment option for [AKs], offering a patient-directed approach to managing this common skin condition.

Actikerall™: A Powerful New Weapon Against Actinic Keratoses

The study found that [Actikerall™] was superior to [diclofenac 3% gel] in achieving complete clinical clearance of [AKs]. This suggests that Actikerall™ may be a more effective treatment option for patients with this condition. The fact that Actikerall™ can be applied by patients themselves adds to its convenience and accessibility.

A Smoother Path to Skin Health: Actikerall™ Offers Hope

This research offers hope for patients with [AKs] by introducing a convenient and effective treatment option. Actikerall™ provides a patient-directed approach to managing this common skin condition, empowering individuals to take control of their health. It's like discovering a soothing balm in the vast, harsh desert of skin ailments – a source of comfort and relief for those seeking a smoother path to healthy skin.

Dr.Camel's Conclusion

This study highlights the potential of Actikerall™ as a promising new treatment option for actinic keratoses. Its efficacy and patient-directed approach offer a convenient and effective solution for managing this common skin condition. Actikerall™ represents a valuable tool for promoting healthy skin, offering a sense of relief and empowerment for those seeking to navigate the challenges of skin ailments.

Date :
  1. Date Completed 2017-04-07
  2. Date Revised 2017-04-07
Further Info :

Pubmed ID

27223248

DOI: Digital Object Identifier

Actikerall, actinic keratosis, antineoplastic antimetabolite, drug combinations, immunosuppressive agents, keratolytic agents, salicylic acid, skin neoplasms, topical therapy

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.